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Aortic stenosis (AS) is the most common valvular disease requiring valve replacement. Its
prevalence increases with age. When the severity of AS is only mild to moderate, it is well
tolerated. When it becomes severe, AS confers significant morbidity and mortality. Adverse
events can be avoided if it is possible to prevent or retard the progression from mild or
moderate AS to severe AS. Progression of AS parallels the progression of sclerotic changes
involving the aortic valve, which share histological and immunochemical similarities with the
process of atherosclerosis. Far from being just a degenerative process, the development of AS
is a complex and highly regulated process with a number of modifiable factors. One of the key
factors appears to be lipoproteins, which are intimately involved in several pathways crucial to
the development of AS. The importance of lipoproteins is further supported by epidemio-
logical and clinical studies showing a strong association between lipoproteins and AS. The
time has come to initiate prospective studies to assess the effect of cholesterol lowering on the
progression of AS. (J Am Coll Cardiol 2003;42:593–9) © 2003 by the American College
of Cardiology Foundation
Aortic stenosis (AS) is the most common valvular disease in
the western world (1–3). It is associated with significant
mortality and morbidity. The prevalence increases with age
such that it affects about 3% of the elderly population and is
the most common reason for valve replacement (1–4). It
will be an increasingly important health issue in view of the
improving life expectancy of the population. Mild to mod-
erate AS is well tolerated and usually produces no symptoms
(5,6). On the other hand, severe AS is associated with
significant morbidity and mortality, and valve replacement is
generally required (3,4). An effective strategy to prevent or
retard the progression from mild or moderate AS to severe
AS should yield major health benefits.
HISTOLOGY OF AS
Over the past 30 years, dramatic changes in the etiology of
AS have occurred. In developed countries, the number of
patients with rheumatic AS has dwindled, and the main
types of the condition are now calcific bicuspid and tricuspid
AS (1–3). The histologic findings of nonrheumatic AS are
well recognized (7–11). The “early lesions” in mild AS
valves are characterized by subendothelial thickening with
disruption of the basement membrane, accumulation of
intra- and extracellular lipids, and cellular infiltration with
macrophages (9–12). The adjacent fibrosa is thickened and
demonstrates accumulation of protein, lipid, and calcium.
Both foam cell and non-foam cell macrophages are present.
The abnormalities are concentrated on the aortic side of the
non-coaptational portion of the cusps, and more marked in
valves with severe AS (7–12). The cusps of severe AS valves
are diffusely thickened with degeneration of structural com-
ponents. Macroscopic calcific nodules are invariably present
and located at the area of maximal cusp flexion, restricting
cusp excursion. These abnormalities result in thickened and
stiff cusps that have little systolic excursion, leading to
obstruction of left ventricular outflow (7–11).
In adult patients, the dominant feature of severe AS, be it
bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV),
is the presence of calcification, which can be quite extensive
(1–3,13). Although it has been suggested that the distribu-
tion of calcific deposits may be different in BAVs versus
TAVs, pathologic examination of large numbers of these
valves have shown more similarities than differences (14). In
BAV, calcification tends to be nodular and localized at the
raphe and the base of the valve pockets. In TAV, calcifica-
tion can be nodular but at times more diffuse, and is
localized in the valve pockets and the base of the commis-
sures. Nodular calcification on the TAV is uncommon
before the age of 50 but is frequently detected in younger
patients with BAV (4,15,16). The progression of dystrophic
calcification is more rapid such that AS is a common
complication in BAV patients leading to aortic valve re-
placement at a younger age compared with patients with
tricuspid AS (1,16). On average patients with BAV requir-
ing surgery for AS are a decade younger than those with
tricuspid stenosis, likely related to the propensity for devel-
opment of calcification at an earlier age (1–3,13).
Thus, a wide range of abnormalities can be seen in AS
valves, starting with small areas of fibrosis and thickening to
extensive structural degeneration, nodular thickening, and
dystrophic calcification. These changes appear to be pro-
gressive over a number of years and, when severe, are closely
associated with severe AS. The reasons these changes are
progressive in some patients and relatively static in others
have not been defined.
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PATHOGENESIS OF AS
The conventional view is that AS is a “degenerative”
process, with the valve damage being a result of wear and
tear (1,15,17). Hydrodynamic studies have shown that there
is flow disturbance and near stagnation at the aortic side of
the aortic cusps (17,18). A high mechanical stress occurs at
the flexion area of the aortic cusps near the attachment to
the aorta root and the line of coaptation (17,18). Aortic
endothelium at areas of high mechanical stress demonstrates
subtle changes consistent with mild damage and becomes
more susceptible to lipid deposition and infiltration by
macrophages. This process is accelerated in BAV because
the abnormal cusps and raphe are subject to greater me-
chanical stress (1).
However, only a minority of elderly individuals develop
AS, and AS is not necessarily an inevitable outcome even in
those with BAV (4,16). Factors other than age-related
degeneration must be involved in the development of AS.
Recent studies show that changes in AS are similar to those
in atherosclerosis (Table 1) (12,19–29). The latter also
increases with age but is clearly more than just a degener-
ative process. An intricate interaction of multiple processes
have been demonstrated to be operative in AS valves, such
as evidence of chronic inflammation including the presence
of macrophages and T-lymphocytes (9,12,21), accumula-
tion of apolipoproteins in addition to lipids (12,20,22,23),
detection of proteins such as osteopontin implicated in
calcification (24), and the detection of calcifying valve cells
with osteoblast-like activities (25,26). These findings sug-
gest that the development of AS is a highly regulated, active
process, which is potentially modifiable, rather than being
an inevitable outcome of aging.
CELLULAR AND MOLECULAR PROCESSES IN AS
Increased valve thickness is a requisite finding in AS, caused
by the combined effect of increased cellularity, lipid accu-
mulation, and extracellular matrix deposition (9,12). Calci-
fication is also a dominant feature, particularly when AS is
severe (1,9). Recent studies have provided insights into the
cellular and subcellular mechanisms underlying these mac-
roscopic changes. Figure 1 illustrates the multiple pathways
in the genesis of valvular AS, with lipoproteins being a key
component in many of these pathways (19,20). The initi-
ating event appears to be endothelial injury at areas of
mechanical stress, predisposing to infiltration by plasma
lipoproteins similar to what is known to happen in the
development of atherosclerosis in susceptible arterial walls
(17,18). Another intriguing possibility is that the sequence
of events may be triggered by an infective organism such as
Chlamydia pneumoniae, which can be detected in half of the
AS valves, but the role of infective agents in AS requires
further studies (27,28). Stenotic “degenerative” aortic valves
have a much larger amount of lipids than non-stenotic
valves (12). Lipid deposition tends to be localized to the
aortic surface of the flexion areas, which are under high
mechanical strain and lower shear stress. The abnormal
mechanical forces are likely to be more prominent in BAV,
leading to a greater degree of lipid deposition at an earlier
age. Co-localization of components of atherogenic apoli-
poproteins (apo-B, apo-[a], and apo-E) has been demon-
strated in close proximity to the extracellular lipids, strongly
suggesting that the lipid deposits are derived from plasma
lipoproteins (20,23). This is followed by oxidative modifi-
cation, and after more extensive modification the oxidized
particles are taken up by macrophages to form foam cells
(12,23). Oxidized low-density lipoprotein (LDL) has been
shown to have prothrombotic effects, as well as to be highly
cytotoxic for many cells, including endothelial cells and
valve fibroblasts. It is suggested that fibroblasts, upon
exposure to oxidized LDL, release matrix vesicles which
form the nidus for calcification (24,25,30). Apolipoprotein
deposition in early AS lesions resembles closely the process
in early lesions of atherosclerosis (12). It has a predilection
for areas of low shear stress and is associated with accumu-
lation of macrophages, T-lymphocytes, and matrix proteins
such as proteoglycans (12,20).
In addition to macrophages, a large number of
T-lymphocytes are present in the subendothelial and fibrosa
layers of stenotic valves (12,21). They co-localize near
calcific nodules. T-lymphocytes appear to play an important
part in the development of AS. They are activated, as
evidenced by the expression of interleukin II receptors. They
release several cytokines, including transforming growth
factor (TGF)-beta, which is a potent activator of extracel-
lular matrix formation. Recently the presence of calcifying
Abbreviations and Acronyms
AS  aortic stenosis
BAV  bicuspid aortic valve
LDL  low-density lipoprotein
TAV  tricuspid aortic valve
TGF  transforming growth factor
Table 1. Comparison of Sclerotic Process in Aortic Stenosis
With That in Atherosclerosis
Aortic
Stenosis Atherosclerosis
Inflammatory changes  
Calcifying cells and mediators  
Calcification  
Heterotopic ossification  
Lipoproteins  
Oxidized lipids  
Role of smooth muscle  
Role of infective agents  
  present;   prominent feature;   absent;   suggestive.
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valve cells has been demonstrated in stenotic valves (25,26).
The origin of these cells is still unclear, but they appear to
be a population of interstitial cells that naturally reside in
cardiac valves. These cells undergo a phenotypic transfor-
mation to become osteoblast-like cells that spontaneously
form calcific nodules (25,26). Their activities are modulated
by growth factors including TGF-beta and hydroxycholes-
terol, which is one of the oxidized sterols (25,26,31). Under
the stimulation of growth factors, these cells produce
proteins that are instrumental in calcification. These include
osteopontin, osteonectin, and alkaline phosphatase. Fibro-
blasts in AS valves appear to be different from fibroblasts in
normal valves in that they secrete alpha-actin and desmin in
addition to vimentin (30). The majority of these cells also
express histocompatibility antigens (HLA-DR molecules)
usually associated with immunocompetent cells (24). In
addition, fibroblasts may be capable of releasing cytokines,
including osteopontin, and likely play an important role in
the development of fibrosis and calcification, which are
found commonly in AS valves. Furthermore, endochondral
bone formation may occur (24,29).
The findings of these recent studies demonstrate a close
association between lipids and calcification, both of which
are invariably present in stenotic valves. The sclerosing
process in aortic valves is a complicated one, but lipids
appear to play an integral part, as they are involved in
multiple pathways required for the development of fibrosis
and calcification. These observations underscore that AS
may not be an inevitable degenerative process of aging, but
rather is an active process that involves multiple pathways
and is thus potentially modifiable (6,11).
LIPIDS AND AS
Animal models. The effect of hypercholesterolemia on the
development of sclerotic changes involving the heart valves
has been demonstrated. Rats on an atherogenic diet for up
to 15 months showed prominent lipid plaques on the aortic
surface of aortic cusps near the attachment to the aortic wall,
which are the typical areas of involvement in human AS
(32). Sarphie (33) studied the topographic changes of the
aortic valve in rabbits on a cholesterol-enriched diet and
showed that there were dramatic changes in the endothelial
cells lining the arterial surfaces but not those lining the
ventricular surface of the aortic cusps. The changes included
a corrugated endothelial surface contour, interendothelial
fenestra, and subendothelial foam cells. A recent study
showed that mice with hyperlipidemia due to over expres-
sion of apolipoprotein E4 all developed severe AS in
addition to coronary disease (34). Finally, in rabbits on a
high-cholesterol diet, sclerotic changes of the aortic valve,
including a large number of foam cells, have been shown.
Osteopontin expression was also detected. This proliferative
atherosclerosis-like process can be inhibited by a statin (35).
Clinical evidence. Valvular and supravalvular AS are well
known in subjects with familial hypercholesterolemia (36–
39), and AS may regress with aggressive reduction of serum
cholesterol. In fact, sclerotic changes of the aortic valve are
ubiquitous in homozygotes and common in heterozygotes
(40). The histological picture of AS in these patients bears
close resemblance to that of calcific “degenerative” AS
(38–40).
In view of the similarity in histology between the scle-
Figure 1. Pathogenetic mechanisms in aortic valve stenosis. Lipoproteins are involved in multiple pathways, which lead to fibrosis and calcification. From
O’Brien et al. (20), Arterioscler Thromb Vasc Biol 1996, reprinted with permission. LDL  low-density lipoprotein.
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rosing process of AS and atherosclerosis, it is logical to
presume that risk factors for atherosclerosis may also be
important in the development of AS. The studies looking at
the association of atherosclerotic risk factors with AS are
summarized in Table 2 (41–52).
The two early case control studies showed contradictory
results (41,42). In both studies, the cases and the control
subjects were largely drawn from patients referred for
cardiac catheterization and thus expected to have a high
prevalence of atherosclerotic risk factors. The studies by
Aronow et al. (43,50) examined patients over 80 years of age
in a chronic care facility, and the prospective study by
Lindroos et al. (45) dealt with subjects at least 75 years of
age. The results of these two studies are obviously limited in
terms of their generalizability. The largest prospective study
in this regard is the Cardiovascular Health Study. This
population-based study of the elderly, with extensive clinical
and echocardiographic data, reported a positive association
of aortic valve disease, which comprised of AS in 2% and
aortic sclerosis in 26% of the total cohort, with risk factors
including age, male gender, history of hypertension, and
high lipoprotein (a) and LDL cholesterol levels (47). In a
retrospective study, Mohler et al. (44) compared risk factors
for AS in BAV versus TAV in surgical patients who had
aortic valve replacement for AS. Race, male gender, and low
triglyceride levels were correlated with age at surgery in
bicuspid AS, whereas male gender and smoking were the
risk factors for patients with degenerative tricuspid AS.
Many of the studies looking at atherosclerotic risk factors
in AS are limited by the use of retrospective data, varying
definition of aortic valve disease, and referral bias. In only
five of these studies was the morphology of the aortic valve
specifically assessed. Bicuspid aortic valve accounted for
39% of the AS cases in the case control study of Hoagland
et al. (42) and 57% of the surgical-pathologic study of
Mohler et al. (44), 42% of the surgical series by Chui et al.
(51), and 0% in the case control study of Peltier et al. (52).
The study by Wilmshurst et al. (48) found that cholesterol
was higher in patients with AS compared with controls. The
patients had severe AS and were drawn from those referred
for cardiac catheterization. Only triglyceride and cholesterol
levels were compared between the two groups. Peltier et al.
(52) included only patients with calcific TAV, and the valve
morphology was confirmed at surgery in all cases. The
controls in their study were patients who required valve
surgery for valvular regurgitation. They showed that total
cholesterol200 mg/dl, in addition to hypertension, smok-
ing, and a high body mass index were associated with AS.
However, they did not assess the effects of the different
cholesterol components, including LDL and high-density
lipoprotein cholesterol levels.
The general lack of appreciation of the significance of
BAV in patients with AS is intriguing and likely related to
the difficulty in reliably detecting BAV before surgery or
autopsy examination. We prospectively identified 100 pa-
tients with BAV from patients referred to our center for
echocardiographic assessment (49). Bicuspid aortic valve
patients with AS were matched with BAV patients with no
significant stenosis. We showed that total cholesterol was
the most significant risk factor for AS (odds ratio 1.77, p 
0.01), despite relatively normal cholesterol levels in both
groups (5.5  1.1 mmol/l in cases vs. 4.9  0.9 mmol/l in
Table 2. Risk Factors Associated with Aortic Stenosis
Author Study Design n
Mean Age
(yrs) Positive Risk Factors
Deutscher et al. (1983) (41) Case control 54 cases NA Hypercholesterolemia, diabetes
359 controls NA
Hoagland et al. (1985) (42) Case control 105 cases (41 BAV) 66 None
439 controls
Aronow et al. (1987) (43)* Hospital survey 571 82 Hypertension, hypercholesterolemia, diabetes,
low HDL cholesterol
Mohler et al. (1991) (44) Retrospective 39 BAV 62 Race, gender, low triglyceride, smoking
30 degenerative 72
Lindroos et al. (1994) (45)* Prospective 501 75 Hypertension, low BMI
Boon et al. (1997) (46) Retrospective echo database 515 cases 67 Age, hypertension, hypercholesterolemia
562 controls
Stewart et al. (1997) (47)* Prospective 5,201 73 Gender, age, hypertension, lipoprotein (a),
LDL cholesterol
Wilmshurst et al. (1997) (48) Prospective case control 20 cases (6 BAV) 66 Cholesterol
20 controls
Chan et al. (2001) (49) Prospective case control 48 cases (all BAV) 56 Cholesterol, history of hypertension
52 controls (all BAV)
Aronow et al. (2001) (50) Retrospective 180 cases 82 Gender, smoking, hypertension, diabetes,
cholesterol, not on statin
Chui et al. (2001) (51) Retrospective case control 43 cases (18 BAV) 66 Cholesterol
40 controls
Peltier et al. (2003) (52) Prospective case control 220 cases 68 Hypertension, smoking, high BMI, cholesterol
220 controls
*Includes cases with sclerotic changes of the aortic valve and/or aortic root.
BAV  bicuspid aortic valve; BMI  body mass index; HDL  high-density lipoprotein; LDL  low-density lipoprotein; NA  not available.
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controls). An important aspect of our study is that these
were largely ambulatory, asymptomatic, young patients
(mean age 56 years).
Taken together, these studies showed that atherosclerotic
risk factors, particularly hypercholesterolemia, are associated
with calcific AS in both BAVs and TAVs. However, there
are differences between the processes underlying AS and
atherosclerosis (Table 1). Only one-half of the patients with
AS have coronary artery disease, and a minority of patients
with coronary artery disease have concomitant AS (53).
Factors accounting for the discordance between the two
processes have not been well defined, but may be related to
the presence of other pathways, such as those involving the
angiotensin-converting enzyme and vitamin D, both of
which have been implicated in the development of AS
(54,55). A recent study suggested that the B allele of the
vitamin D receptor may be a predisposing factor for AS
(55). Future studies will likely identify other genetic markers
specific to the process of AS or atherosclerosis.
PROGRESSION AND CLINICAL SIGNIFICANCE OF AS
Recent evidence suggests that aortic sclerosis is a common
finding in the elderly and a precursor of AS (56,57).
Faggiano et al. (56) reported that about one-third of the
patients with aortic sclerosis developed some degree of AS
in a follow-up of four years. When mild or moderate AS
ensues, the overall rate of progression becomes more pre-
dictable at about 7 mm Hg increase in mean gradient per
year, although substantial variability occurs in individual
patients (58–71). Table 3 summarizes the results of studies
that have examined this question.
In the older studies, the observations were based on
catheter-derived hemodynamic data (5,58,59), whereas the
more recent studies obtained these parameters using non-
invasive Doppler echocardiography (6,60–71). Only three
of these studies were prospective in nature (6,62,66). The
annual increase in the aortic valve gradient was quite similar
among the different studies, averaging about 7 mm Hg per
year, despite the differences in study design, baseline aortic
valve gradients, and the duration of follow-up. Factors
predictive of a more rapid progression have been proposed.
Palta et al. (68) found that initial aortic valve area, current
smoking, and serum calcium level were positively correlated
with AS progression in 170 patients who had paired
echocardiograms. Patients with cholesterol level 200
mg/dl had twice the rate of progression compared with
those with lower cholesterol level, although cholesterol was
not an independent predictor in the multiple regression
analysis. In the study by Novaro et al. (70), the predictors
for more rapid progression were age and not being on statin
therapy. The annualized decreases in aortic valve area were
0.11 cm2 in the patients not taking a statin and 0.06 cm2 in
those on a statin. There was a modest relationship between
the change in LDL cholesterol level and the change in
aortic valve area. Bellamy et al. (71) also showed an
association between statin use and slower AS progression,

















Cheitlin et al. (1979) (58) Catheter 29 45 3.6 34 7.6 NA Progressive symptom
Wagner and Selzer (1982) (59) Catheter 50 54 3.5 38 5.4 NA Age, AV calcification
Nitta et al. (1987) (60) Catheter 11 NA 3.0 23 7.7 NA Age
Turina et al. (1987) (61) Catheter 29 NA 7.0 50 3.4 NA None
Otto et al. (1989) (62)† Doppler 42 66 1.7 35 8.0 0.10 Female, symptoms
Roger et al. (1990) (63) Doppler 112 69 2.1 35* 4.8* NA Female, symptoms
Davies et al. (1991) (5) Catheter 65 54 7.0 10 6.5 NA AV calcification
Faggiano et al. (1992) (64) Doppler 45 72 1.5 64* 15.0* 0.10 Baseline pressure
gradient
Peter et al. (1993) (65) Doppler 49 58 2.6 38* 7.2* NA Age, CAD
Ilvanainan et al. (1996) (66)† Doppler 333 81 3.0 7 NA 0.06 BMI
Otto et al. (1997) (6)† Doppler 123 63 2.5 29 7.0 0.12 Baseline pressure
gradient,
symptoms
Bahler et al. (1999) (67) Doppler 91 68 1.8 16 4.9 0.08 AV calcification,
baseline AVA
Palta et al. (2000) (68) Doppler 170 71 2.0 20 7.0 0.10 Baseline AVA,
smoking, serum
calcium
Ngo et al. (2001) (69) Doppler 123 70 2.5 31* 6.3* NA History of smoking,
BMI
Novaro et al. (2001) (70) Doppler 174 68 1.8 15 NA 0.11 Age, not on statin
0.06 (on statin)
Bellamy et al. (2002) (71) Doppler 156 77 3.7 21 5.3 0.09 Not on statin
2.9 (on statin) 0.04 (on statin)
*Peak gradient. †Prospective studies.
AV  aortic valve; AVA  aortic valve area; BMI  body mass index; CAD  coronary artery disease.
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but they did not find a significant correlation between
progression of AS and the cholesterol levels. It is notewor-
thy that the morphology of aortic valve, that is BAV versus
TAV, was not examined in most of these studies, likely
because of the inability to determine valvular morphology by
cardiac catheterization or even by echocardiography. In the
studies of Otto et al. (6) and Bellamy et al. (71), the rate of
progression in AS severity was no different in those with a
BAV versus TAV.
Recent studies utilizing electron beam tomography pro-
vide further evidence to support the importance of choles-
terol in the genesis of AS. Calcification of aortic cusps,
invariably present in adults with AS, can be quantitated by
electron beam tomography (72,73). Pohle et al. (73) showed
a positive correlation between LDL cholesterol level and
progression of aortic valve calcification. Treatment with a
statin appears to reduce the progression of aortic valve
calcification. In the study of Shavelle et al. (72), statin
treatment reduced almost by half the number of patients
with progression of aortic valve calcification in a mean
interval of 2.5 years.
Summary. Aortic stenosis is the most common valvular
disease, but adverse events are uncommon until the devel-
opment of severe AS (63–65). Regular follow-up of AS
patients is important to monitor hemodynamic progression
and development of symptoms. Recent studies showed that
AS is an active process, which is highly regulated and
potentially modifiable. Lipids appear to play an important
role in the development and progression of AS, and there is
mounting evidence that cholesterol lowering may retard or
prevent the progression. An effective medical strategy to
slow or stop the progression of AS will have major public
health benefits, in view of higher prevalence of AS with age
and increasing life expectancy of the general population.
Prevention of the development of severe AS is a novel idea,
which has not been tested. The time has come for such a
study in patients with mild to moderate AS. The result of
the study will have a direct impact on the treatment of AS
patients and will expand our understanding of the patho-
genesis of AS.
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